Control of cancer-related anemia with erythropoietic agents:a review of evidence for improved quality of life and clinical outcomes
Open Access
- 1 April 2003
- journal article
- review article
- Published by Elsevier in Annals of Oncology
- Vol. 14 (4) , 511-519
- https://doi.org/10.1093/annonc/mdg167
Abstract
Background: Anemia occurs frequently in patients with cancer and is associated with impaired health-related quality of life (HRQOL). Treatment of anemia results in significant improvements in energy, activity and overall HRQOL, particularly among patients with mild-to-moderate anemia. Importantly, studies have indicated that anemia may have a negative impact on the success of radiotherapy, reducing survival and locoregional control. Recent preclinical and preliminary clinical data have also suggested that anemia may be associated with poorer outcomes following chemotherapy or surgery. Materials and methods: Data for review were identified and selected from searches of the literature published from January 1990 through to October 2002 using Medline®, and searches of proceedings from key international oncology and hematology meetings. Results: A wealth of data indicate that treatment of anemia improves HRQOL in patients with cancer. Prospective studies exploring survival and/or treatment outcomes in anemic cancer patients are currently in their early stages, preventing any firm conclusions from being drawn, although they do indicate a benefit in treating anemia. Conclusions: Recent studies support the use of erythropoietic agents in anemic cancer patients as a means of raising their hemoglobin levels and consequently improving their HRQOL. Randomized, controlled trials are needed to determine whether treating anemia with erythropoietic agents will improve other outcomes following therapy.Keywords
This publication has 51 references indexed in Scilit:
- Impact of hemoglobin levels before and during concurrent chemoradiotherapy on the response of treatment in patients with cervical carcinomaCancer, 2001
- Epoetin alfa overcomes much of the QOL deficit seen in anaemic cancer patientsEuropean Journal Of Cancer, 2001
- Prognostic significance of peri-operative blood transfusion following radical resection for oesophageal carcinomaEuropean Journal of Surgical Oncology, 2000
- Cost Effectiveness, Quality-Adjusted Life-Years and Supportive CarePharmacoEconomics, 1999
- What are cancer patients willing to pay for prophylactic epoetin alfa?Cancer, 1998
- A practical prognostic index for inoperable non-small-cell lung cancerZeitschrift für Krebsforschung und Klinische Onkologie, 1997
- Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement systemJournal of Pain and Symptom Management, 1997
- Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapyCancer, 1995
- Erythropoietin for anaemia in cancer patientsEuropean Journal Of Cancer, 1993
- Decreased Erythropoietin Response in Patients with the Anemia of CancerNew England Journal of Medicine, 1990